annual CFO:
-$40.66M-$17.27M(-73.88%)Summary
- As of today (September 15, 2025), AKBA annual cash flow from operations is -$40.66 million, with the most recent change of -$17.27 million (-73.88%) on December 31, 2024.
- During the last 3 years, AKBA annual CFO has risen by +$212.31 million (+83.93%).
- AKBA annual CFO is now -170.22% below its all-time high of $57.91 million, reached on December 31, 2016.
Performance
AKBA Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
$22.34M+$35.93M(+264.46%)Summary
- As of today (September 15, 2025), AKBA quarterly cash flow from operations is $22.34 million, with the most recent change of +$35.93 million (+264.46%) on June 1, 2025.
- Over the past year, AKBA quarterly CFO has increased by +$32.41 million (+321.98%).
- AKBA quarterly CFO is now -76.64% below its all-time high of $95.67 million, reached on December 31, 2016.
Performance
AKBA quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
-$2.40M+$32.41M(+93.10%)Summary
- As of today (September 15, 2025), AKBA TTM cash flow from operations is -$2.40 million, with the most recent change of +$32.41 million (+93.10%) on June 1, 2025.
- Over the past year, AKBA TTM CFO has increased by +$36.57 million (+93.83%).
- AKBA TTM CFO is now -102.92% below its all-time high of $82.26 million, reached on June 30, 2017.
Performance
AKBA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
AKBA Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -73.9% | +322.0% | +93.8% |
| 3 y3 years | +83.9% | +172.9% | +98.6% |
| 5 y5 years | +84.2% | -40.0% | +98.2% |
AKBA Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -73.9% | +83.9% | -33.9% | +140.9% | at high | +98.6% |
| 5 y | 5-year | -73.9% | +84.2% | -40.0% | +131.6% | at high | +99.0% |
| alltime | all time | -170.2% | +84.2% | -76.6% | +116.2% | -102.9% | +99.1% |
AKBA Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $22.34M(-264.5%) | -$2.40M(-93.1%) |
| Mar 2025 | - | -$13.59M(+204.2%) | -$34.81M(-14.4%) |
| Dec 2024 | -$40.66M(+73.9%) | -$4.47M(-33.3%) | -$40.66M(+5.6%) |
| Sep 2024 | - | -$6.70M(-33.5%) | -$38.50M(-1.2%) |
| Jun 2024 | - | -$10.07M(-48.2%) | -$38.97M(+54.2%) |
| Mar 2024 | - | -$19.43M(+741.9%) | -$25.28M(+8.1%) |
| Dec 2023 | -$23.38M(-68.0%) | -$2.31M(-67.8%) | -$23.38M(-69.1%) |
| Sep 2023 | - | -$7.17M(-297.5%) | -$75.75M(+117.8%) |
| Jun 2023 | - | $3.63M(-120.7%) | -$34.78M(-49.6%) |
| Mar 2023 | - | -$17.54M(-67.9%) | -$69.07M(-5.6%) |
| Dec 2022 | -$73.15M(-71.1%) | -$54.68M(-261.7%) | -$73.15M(-10.0%) |
| Sep 2022 | - | $33.80M(-210.3%) | -$81.28M(-52.6%) |
| Jun 2022 | - | -$30.66M(+41.8%) | -$171.36M(-15.9%) |
| Mar 2022 | - | -$21.62M(-65.6%) | -$203.84M(-19.4%) |
| Dec 2021 | -$252.97M(+129.2%) | -$62.81M(+11.6%) | -$252.97M(+14.5%) |
| Sep 2021 | - | -$56.27M(-10.9%) | -$220.94M(+15.1%) |
| Jun 2021 | - | -$63.14M(-10.7%) | -$191.91M(+109.6%) |
| Mar 2021 | - | -$70.75M(+129.8%) | -$91.55M(-17.1%) |
| Dec 2020 | -$110.39M(-57.1%) | -$30.78M(+13.0%) | -$110.39M(-35.7%) |
| Sep 2020 | - | -$27.24M(-173.2%) | -$171.74M(+28.6%) |
| Jun 2020 | - | $37.22M(-141.5%) | -$133.51M(-36.1%) |
| Mar 2020 | - | -$89.59M(-2.8%) | -$209.10M(-18.8%) |
| Dec 2019 | -$257.44M(+164.1%) | -$92.14M(-938.4%) | -$257.44M(+7.7%) |
| Sep 2019 | - | $10.99M(-128.6%) | -$239.00M(-8.9%) |
| Jun 2019 | - | -$38.37M(-72.2%) | -$262.45M(+22.0%) |
| Mar 2019 | - | -$137.93M(+87.2%) | -$215.09M(+120.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$97.49M(+73.6%) | -$73.70M(+491.4%) | -$97.49M(+142.7%) |
| Sep 2018 | - | -$12.46M(-238.5%) | -$40.17M(-51.2%) |
| Jun 2018 | - | $9.00M(-144.2%) | -$82.33M(+23.0%) |
| Mar 2018 | - | -$20.33M(+24.1%) | -$66.96M(+19.2%) |
| Dec 2017 | -$56.16M(-197.0%) | -$16.38M(-70.0%) | -$56.16M(-200.5%) |
| Sep 2017 | - | -$54.62M(-324.2%) | $55.89M(-32.1%) |
| Jun 2017 | - | $24.36M(-355.7%) | $82.26M(+165.8%) |
| Mar 2017 | - | -$9.53M(-110.0%) | $30.94M(-46.6%) |
| Dec 2016 | $57.91M(-210.5%) | $95.67M(-438.7%) | $57.91M(-195.4%) |
| Sep 2016 | - | -$28.24M(+4.8%) | -$60.68M(+46.3%) |
| Jun 2016 | - | -$26.95M(-254.6%) | -$41.46M(+55.7%) |
| Mar 2016 | - | $17.43M(-176.1%) | -$26.63M(-49.2%) |
| Dec 2015 | -$52.41M(+90.7%) | -$22.91M(+153.7%) | -$52.41M(+35.4%) |
| Sep 2015 | - | -$9.03M(-25.5%) | -$38.70M(+9.7%) |
| Jun 2015 | - | -$12.12M(+45.2%) | -$35.27M(+18.3%) |
| Mar 2015 | - | -$8.35M(-9.3%) | -$29.82M(+8.5%) |
| Dec 2014 | -$27.48M(+142.5%) | -$9.20M(+64.3%) | -$27.48M(+18.5%) |
| Sep 2014 | - | -$5.60M(-16.0%) | -$23.19M(+13.0%) |
| Jun 2014 | - | -$6.67M(+11.0%) | -$20.52M(+29.8%) |
| Mar 2014 | - | -$6.01M(+22.4%) | -$15.81M(+39.5%) |
| Dec 2013 | -$11.33M(+57.1%) | -$4.91M(+67.1%) | -$11.33M(+76.4%) |
| Sep 2013 | - | -$2.94M(+50.1%) | -$6.42M(+84.3%) |
| Jun 2013 | - | -$1.96M(+27.9%) | -$3.49M(+127.9%) |
| Mar 2013 | - | -$1.53M | -$1.53M |
| Dec 2012 | -$7.21M(-48.9%) | - | - |
| Dec 2011 | -$14.12M | - | - |
FAQ
- What is Akebia Therapeutics, Inc. annual cash flow from operations?
- What is the all time high annual CFO for Akebia Therapeutics, Inc.?
- What is Akebia Therapeutics, Inc. annual CFO year-on-year change?
- What is Akebia Therapeutics, Inc. quarterly cash flow from operations?
- What is the all time high quarterly CFO for Akebia Therapeutics, Inc.?
- What is Akebia Therapeutics, Inc. quarterly CFO year-on-year change?
- What is Akebia Therapeutics, Inc. TTM cash flow from operations?
- What is the all time high TTM CFO for Akebia Therapeutics, Inc.?
- What is Akebia Therapeutics, Inc. TTM CFO year-on-year change?
What is Akebia Therapeutics, Inc. annual cash flow from operations?
The current annual CFO of AKBA is -$40.66M
What is the all time high annual CFO for Akebia Therapeutics, Inc.?
Akebia Therapeutics, Inc. all-time high annual cash flow from operations is $57.91M
What is Akebia Therapeutics, Inc. annual CFO year-on-year change?
Over the past year, AKBA annual cash flow from operations has changed by -$17.27M (-73.88%)
What is Akebia Therapeutics, Inc. quarterly cash flow from operations?
The current quarterly CFO of AKBA is $22.34M
What is the all time high quarterly CFO for Akebia Therapeutics, Inc.?
Akebia Therapeutics, Inc. all-time high quarterly cash flow from operations is $95.67M
What is Akebia Therapeutics, Inc. quarterly CFO year-on-year change?
Over the past year, AKBA quarterly cash flow from operations has changed by +$32.41M (+321.98%)
What is Akebia Therapeutics, Inc. TTM cash flow from operations?
The current TTM CFO of AKBA is -$2.40M
What is the all time high TTM CFO for Akebia Therapeutics, Inc.?
Akebia Therapeutics, Inc. all-time high TTM cash flow from operations is $82.26M
What is Akebia Therapeutics, Inc. TTM CFO year-on-year change?
Over the past year, AKBA TTM cash flow from operations has changed by +$36.57M (+93.83%)